Inside Science reporter Yuen Yiu writes that MIT researchers have developed a new technique for producing nanoscale structures using a 3-D printing method that shrinks objects. Yiu explains that the new technique operates by “first creating a bigger structure inside of a gel, then shrinking the gel, which brings the structure down to one-thousandth the volume of the original.”
HealthDay News reporter E.J. Mundell writes that MIT researchers have developed an ingestible capsule that can be used to monitor health a patient’s health. “The capsule could deliver drugs as well as sense the condition of its surroundings in the gut, including infections or allergic reactions,” Mundell explains.
MIT researchers have developed a new method to shrink 3-D printed objects, reports Douglas Heaven for New Scientist. The technique can be used to create a wide variety of shapes using different materials. “In the 1970s hobbyists built their own computers at home,” explains Prof. Edward Boyden. “Maybe people can now make their own chips.”
Boston Globe reporter Jessie Scanlon spotlights Prof. Regina Barzilay’s work developing machine learning systems that can identify patients at risk of developing breast cancer. Barzilay is creating “software that aims to teach a computer to analyze mammogram images more effectively than the human eye can and to catch signs of cancer in its earliest phases.”
MIT researchers have developed a new technique to measure cancer cells that provides insight into how certain cells respond to treatment, reports the Xinhua news agency. The findings could be used to help develop new drug targets, making current treatments more effective.
MIT researchers have developed a new injectable material that can deliver medication through cartilage and could one day be used to help reverse osteoarthritis, reports Katie Camero for The Boston Globe. Camero explains that the new material “can penetrate deep into the tissue, delivering drugs that can potentially help the chondrocytes heal cartilage.”
STAT reporter Kate Sheridan writes about MIT startup SQZ Biotech, which is developing a “technology that will squeeze cells to open up tiny pores in their membranes to deliver gene therapies or medicines straight into the cell.”
MIT startup Lyndra has found that an ingestible device originally developed by researchers from MIT and Brigham and Women’s Hospital can help tackle the problem of medication adherence, reports Kate Sheridan for STAT. The new technology could make it possible for patients to take “one pill a week for conditions as varied as Alzheimer’s, addiction, allergies, malaria, schizophrenia, high cholesterol, and HIV.”
A team of researchers led by Prof. J. Christopher Love has developed a system to produce on-demand clinical-grade vaccines and drugs, writes Dr. Francis Collins on the NIH Director’s Blog. In addition to allowing on site production for hospitals the systems could also “produce biologic treatments specially tailored to attack the cancer of a particular individual,” suggests Collins.
Writing for STAT, Karen Weintraub spotlights Prof. J. Christopher Love’s work developing a new desktop drug manufacturing process that can produce thousands of doses of biopharmaceuticals on demand. “I think in the long run there’ll be an opportunity to think about manufacturing for patients in a new way,” says Love.
Boston Herald reporter Alexi Cohan highlights a new lab at MIT, led by Prof. Tyler Jacks, that will investigate how the immune system can be used to treat and manage pancreatic cancer. “In the long term we hope that the work that we are doing will help us diagnose the disease at even early stage and maybe even prevent it altogether,” Jacks explains.
Boston Globe reporter Martin Finucane writes that MIT researchers have developed sensors that can track dopamine levels in the brain. The sensors could eventually be used to monitor “Parkinson’s patients who receive a treatment called deep brain stimulation,” Finucane explains, adding that the sensors could “help deliver the stimulation only when it’s needed.”
Researchers from MIT and Brigham and Women’s Hospital have found that cellular changes lead to chronic sinus inflammation, reports Allen Cone for UPI. Cone explains that the findings could also “help patients with chronic inflammatory diseases of barrier tissues, such as asthma, eczema, and inflammatory bowel disease.”
By analyzing thousands of human cells and creating a cellular map of human barrier tissue, MIT researchers have identified the mechanism that may cause chronic allergic inflammation in the sinus, according to Xinhua News Agency. The findings could have “implications on treatment of other chronic inflammatory diseases of barrier tissues, such as asthma, eczema, and inflammatory bowel disease.”
STAT reporter Orly Nadell Farber writes about a new study by MIT researchers that shows glaucoma might be caused by T-cells, an integral component of the human body’s immune system, attacking retinal cells. Farber explains that, “this discovery could unlock a critical new door for treatment options.”